lutikizumab
What stands out
New approach in eczema
- Binds to IL-1 alpha (an alarm signal released from damaged cells that helps start inflammation) and IL-1 beta (an inflammation signal that activates immune cells)
- Injection every 2 weeks in trials
Derived from FDA substance registry · NCT06718101 · UniProt P01583 · UniProt P01584 · · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Aug 14, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Dec 19, 2024Phase 2 trial startedA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06718101
- Aug 14, 2024Phase 2 trial started · Basic-science trialA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab ClinicalTrials.gov NCT06524635